50 Million of people around the world are currently suffering from Alzheimer's disease - 5.5 million of them in the US. Archer Pharmaceuticals was formed in 2008 to advance drug therapies to slow or prevent the disease. Alzheimer's disease is a growing problem around the world, with devastating consequences for patients, caregivers and families.
As we understand more and more about the disease, it's clear it can be halted. 1 Early Discoveries In the early 1990s, Drs. Michael Mullan and Fiona Crawford, were key researchers who discovered Alzheimer's disease could be caused by abnormalities with a protein called beta-amyloid. 2 What We Know Now Since these early discoveries, many findings have clarified the role of beta-amyloid and other pathologies in Alzheimer's disease.
As we understand more and more about the disease, it's clear it can be halted. 1 Early Discoveries In the early 1990s, Drs. Michael Mullan and Fiona Crawford, were key researchers who discovered Alzheimer's disease could be caused by abnormalities with a protein called beta-amyloid. 2 What We Know Now Since these early discoveries, many findings have clarified the role of beta-amyloid and other pathologies in Alzheimer's disease.
Services
D., has served as the Chief Executive Officer and Chief Scientific Officer for Archer Pharmaceuticals since its inception in 2008. He is also Chairman of the Archer Board. Dr. Mullan has previously served as CEO or CSO of both publicly traded and private drug development companies including the Roskamp Institute which he co-founded in 2003 with Dr. Fiona Crawford and Bob and Diane Roskamp.
Reviews
Be the first to review Archer Pharmaceuticals.
Write a Review
